EPS for RedHill Biopharma Ltd. (RDHL) Expected At $-0.57

April 17, 2018 - By Linda Rogers

RedHill Biopharma Ltd. (NASDAQ:RDHL) Logo

Analysts expect RedHill Biopharma Ltd. (NASDAQ:RDHL) to report $-0.57 EPS on May, 2.They anticipate $0.07 EPS change or 14.00 % from last quarter’s $-0.5 EPS. After having $-0.50 EPS previously, RedHill Biopharma Ltd.’s analysts see 14.00 % EPS growth. The stock increased 0.40% or $0.02 during the last trading session, reaching $4.96. About 157,983 shares traded or 102.77% up from the average. RedHill Biopharma Ltd. (NASDAQ:RDHL) has declined 50.83% since April 17, 2017 and is downtrending. It has underperformed by 62.38% the S&P500.

RedHill Biopharma Ltd. (NASDAQ:RDHL) Ratings Coverage

Among 2 analysts covering RedHill Biopharma (NASDAQ:RDHL), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. RedHill Biopharma had 2 analyst reports since November 14, 2017 according to SRatingsIntel. Roth Capital maintained the stock with “Buy” rating in Tuesday, November 14 report.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company has market cap of $109.39 million. The firm promotes two gastrointestinal products in the U.S., such as Donnatal, a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis; and EnteraGam, a medical food intended for the dietary management under medical supervision of chronic diarrhea and loose stools. It currently has negative earnings. The Company’s clinical-stage pipeline includes TALICIA , an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study and an ongoing confirmatory Phase III study; RHB-104, an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study, a completed proof-of-concept Phase IIa study for multiple sclerosis, and QIDP status for nontuberculous mycobacteria infections; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron with successful top-line results in a Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; RHB-106, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; YELIVA (ABC294640), a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory, and gastrointestinal indications; MESUPRON, a Phase II-stage first-in-class, orally-administered protease inhibitor, targeting pancreatic cancer and other solid tumors; and RIZAPORT (RHB-103), an oral thin film formulation of rizatriptan for acute migraines, with a U.S.

RedHill Biopharma Ltd. (NASDAQ:RDHL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.